British Society of Echocardiography guideline for the TTE assessment of cardiac amyloidosis and the role of ECHO in monitoring disease progression in cardiac amyloidosis

This site is intended for UK healthcare professionals

Sponsorship statement:

This non-promotional video has been developed and funded by Pfizer Ltd. and is intended for UK healthcare professionals only.

British Society of Echocardiography guideline for the TTE assessment of cardiac amyloidosis and the role of ECHO in monitoring disease progression in cardiac amyloidosis

25 February 2026

In this short video, Dr Moody discusses the British Society of Echocardiography guidelines for the TTE assessment of cardiac amyloidosis, and monitoring disease progression.

Speaker

Dr William E Moody, Consultant Cardiologist, Queen Elizabeth Hospital, Birmingham

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and transthyretin amyloid cardiomyopathy, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Reference

Moody, William E et al. “British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.” Echo research and practice vol. 10,1 13. 31 Aug. 2023, doi:10.1186/s44156-023-00028-7

Abbreviations:
ECHO: echocardiography; TTE: transthoracic echocardiography.

PP-UNP-GBR-14075 | March 2026